# Savara Inc: financial statements, quarterly

SVRA · Nasdaq · CIK 1160308 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/svra.md) · [Financials](/companies/svra/financials.md) · [Filings](/companies/svra/filings.md) · [Insiders](/companies/svra/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/svra/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Research and development | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Selling, general and administrative | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating income | $m | [(18.0)](/filings/0000950170-24-125292.md) | [(17.6) d](/filings/0000950170-25-045731.md) | [(22.5)](/filings/0000950170-25-070283.md) | [(23.2)](/filings/0000950170-25-107631.md) | [(26.4)](/filings/0001193125-25-277525.md) | [(31.2) d](/filings/0001193125-26-105076.md) | [(28.4)](/filings/0001193125-26-219371.md) | [(31.4)](/filings/0001193125-26-344585.md) | [(30.3)](/filings/0001193125-25-277525.md) | [(33.4) d](/filings/0001193125-26-105076.md) | [(39.0)](/filings/0001193125-26-219371.md) | [(41.0)](/filings/0001193125-26-344585.md) |
| Interest expense | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Net income | $m | [(16.6)](/filings/0000950170-24-125292.md) | [(16.1) d](/filings/0000950170-25-045731.md) | [(20.3)](/filings/0001193125-25-277525.md) | [(22.2)](/filings/0001193125-25-277525.md) | [(24.2)](/filings/0001193125-25-277525.md) | [(29.0) d](/filings/0001193125-26-105076.md) | [(26.6)](/filings/0001193125-26-344585.md) | [(30.4)](/filings/0001193125-26-344585.md) | [(29.6)](/filings/0001193125-25-277525.md) | [(32.2) d](/filings/0001193125-26-105076.md) | [(37.3)](/filings/0001193125-26-344585.md) | [(40.2)](/filings/0001193125-26-344585.md) |
| Diluted EPS | $ per share | [(0.10)](/filings/0000950170-24-125292.md) | not reported | [(0.11)](/filings/0000950170-25-070283.md) | [(0.12)](/filings/0000950170-25-107631.md) | [(0.11)](/filings/0001193125-25-277525.md) | not reported | [(0.12)](/filings/0001193125-26-219371.md) | [(0.14)](/filings/0001193125-26-344585.md) | [(0.14)](/filings/0001193125-25-277525.md) | not reported | [(0.15)](/filings/0001193125-26-219371.md) | [(0.16)](/filings/0001193125-26-344585.md) |
| Basic EPS | $ per share | [(0.10)](/filings/0000950170-24-125292.md) | not reported | [(0.11)](/filings/0000950170-25-070283.md) | [(0.12)](/filings/0000950170-25-107631.md) | [(0.11)](/filings/0001193125-25-277525.md) | not reported | [(0.12)](/filings/0001193125-26-219371.md) | [(0.14)](/filings/0001193125-26-344585.md) | [(0.14)](/filings/0001193125-25-277525.md) | not reported | [(0.15)](/filings/0001193125-26-219371.md) | [(0.16)](/filings/0001193125-26-344585.md) |

- Revenue: not reported
- Research and development: not reported
- Selling, general and administrative: not reported
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: not reported
- Income tax: not reported
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [27.7](/filings/0000950170-23-062040.md) | [26.6](/filings/0000950170-25-045731.md) | [16.8](/filings/0000950170-24-056954.md) | [23.9](/filings/0000950170-24-095403.md) | [21.4](/filings/0000950170-24-125292.md) | [15.1](/filings/0001193125-26-105076.md) | [19.6](/filings/0000950170-25-070283.md) | [17.4](/filings/0000950170-25-107631.md) | [16.3](/filings/0001193125-25-277525.md) | [33.2](/filings/0001193125-26-344585.md) | [38.8](/filings/0001193125-26-219371.md) | [41.8](/filings/0001193125-26-344585.md) |
| Current assets | $m | [170](/filings/0000950170-23-062040.md) | [166](/filings/0000950170-25-045731.md) | [146](/filings/0000950170-24-056954.md) | [128](/filings/0000950170-24-095403.md) | [226](/filings/0000950170-24-125292.md) | [202](/filings/0001193125-26-105076.md) | [177](/filings/0000950170-25-070283.md) | [151](/filings/0000950170-25-107631.md) | [128](/filings/0001193125-25-277525.md) | [242](/filings/0001193125-26-344585.md) | [209](/filings/0001193125-26-219371.md) | [178](/filings/0001193125-26-344585.md) |
| Total assets | $m | [182](/filings/0000950170-23-062040.md) | [178](/filings/0000950170-25-045731.md) | [158](/filings/0000950170-24-056954.md) | [140](/filings/0000950170-24-095403.md) | [239](/filings/0000950170-24-125292.md) | [213](/filings/0001193125-26-105076.md) | [189](/filings/0000950170-25-070283.md) | [164](/filings/0000950170-25-107631.md) | [141](/filings/0001193125-25-277525.md) | [253](/filings/0001193125-26-344585.md) | [222](/filings/0001193125-26-219371.md) | [192](/filings/0001193125-26-344585.md) |
| Current liabilities | $m | [9.0](/filings/0000950170-23-062040.md) | [10.6](/filings/0000950170-25-045731.md) | [9.8](/filings/0000950170-24-056954.md) | [11.3](/filings/0000950170-24-095403.md) | [12.8](/filings/0000950170-24-125292.md) | [14.7](/filings/0001193125-26-105076.md) | [11.9](/filings/0000950170-25-070283.md) | [13.6](/filings/0000950170-25-107631.md) | [16.8](/filings/0001193125-25-277525.md) | [20.4](/filings/0001193125-26-344585.md) | [15.5](/filings/0001193125-26-219371.md) | [17.6](/filings/0001193125-26-344585.md) |
| Total liabilities | $m | [35.5](/filings/0000950170-23-062040.md) | [37.2](/filings/0000950170-25-045731.md) | [36.4](/filings/0000950170-24-056954.md) | [37.9](/filings/0000950170-24-095403.md) | [39.5](/filings/0000950170-24-125292.md) | [41.4](/filings/0001193125-26-105076.md) | [41.5](/filings/0000950170-25-070283.md) | [43.3](/filings/0000950170-25-107631.md) | [46.5](/filings/0001193125-25-277525.md) | [50.3](/filings/0001193125-26-344585.md) | [45.6](/filings/0001193125-26-219371.md) | [48.5](/filings/0001193125-26-344585.md) |
| Long-term debt | $m | [26.3](/filings/0000950170-23-062040.md) | [26.3](/filings/0000950170-25-045731.md) | [26.4](/filings/0000950170-24-056954.md) | [26.5](/filings/0000950170-24-095403.md) | [26.6](/filings/0000950170-24-125292.md) | [26.6](/filings/0001193125-26-105076.md) | [29.5](/filings/0000950170-25-070283.md) | [29.7](/filings/0000950170-25-107631.md) | [29.8](/filings/0001193125-25-277525.md) | [29.9](/filings/0001193125-26-344585.md) | [30.1](/filings/0001193125-26-219371.md) | [30.1](/filings/0001193125-26-344585.md) |
| Current portion of debt | $m | not reported | not reported | not reported | not reported | not reported | [0.0](/filings/0000950170-25-107631.md) | [0.0](/filings/0000950170-25-070283.md) | [0.0](/filings/0000950170-25-107631.md) | [0.0](/filings/0001193125-25-277525.md) | [0.0](/filings/0001193125-26-105076.md) | [0.0](/filings/0001193125-26-219371.md) | [0.0](/filings/0001193125-26-344585.md) |
| Shareholders' equity | $m | [147](/filings/0000950170-24-125292.md) | [140](/filings/0001193125-26-105076.md) | [122](/filings/0001193125-25-277525.md) | [102](/filings/0001193125-25-277525.md) | [199](/filings/0001193125-25-277525.md) | [171](/filings/0001193125-26-344585.md) | [148](/filings/0001193125-26-344585.md) | [120](/filings/0001193125-26-344585.md) | [94.4](/filings/0001193125-25-277525.md) | [203](/filings/0001193125-26-344585.md) | [176](/filings/0001193125-26-344585.md) | [144](/filings/0001193125-26-344585.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(13.2) d](/filings/0000950170-24-125292.md) | [(15.6) d](/filings/0000950170-25-045731.md) | [(20.6)](/filings/0000950170-25-070283.md) | [(22.5) d](/filings/0000950170-25-107631.md) | [(22.7) d](/filings/0001193125-25-277525.md) | [(23.3) d](/filings/0001193125-26-105076.md) | [(27.2)](/filings/0001193125-26-219371.md) | [(26.3) d](/filings/0001193125-26-344585.md) | [(22.5) d](/filings/0001193125-25-277525.md) | [(25.1) d](/filings/0001193125-26-105076.md) | [(33.0)](/filings/0001193125-26-219371.md) | [(29.7) d](/filings/0001193125-26-344585.md) |
| Capital expenditure | $m | [0.0 d](/filings/0000950170-24-125292.md) | [0.0 d](/filings/0000950170-25-045731.md) | [0.0](/filings/0000950170-25-070283.md) | [0.0 d](/filings/0000950170-25-107631.md) | [0.0 d](/filings/0001193125-25-277525.md) | [(0.0) d](/filings/0001193125-26-105076.md) | [0.0](/filings/0001193125-26-219371.md) | [0.0 d](/filings/0001193125-26-344585.md) | [0.0 d](/filings/0001193125-25-277525.md) | [0.0 d](/filings/0001193125-26-105076.md) | [0.1](/filings/0001193125-26-219371.md) | [0.2 d](/filings/0001193125-26-344585.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [153](/filings/0000950170-23-062040.md) | [153](/filings/0000950170-24-056954.md) | [153](/filings/0000950170-24-095403.md) | [175](/filings/0000950170-24-125292.md) | [183](/filings/0000950170-25-070283.md) | [183](/filings/0000950170-25-107631.md) | [212](/filings/0001193125-25-277525.md) | [216](/filings/0001193125-26-219371.md) | [216](/filings/0001193125-26-344585.md) | [216](/filings/0001193125-25-277525.md) | [253](/filings/0001193125-26-219371.md) | [254](/filings/0001193125-26-344585.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 205,460,015 at 2026-08-11, from the cover of the [10-Q filed 2026-08-11](/filings/0001193125-26-344585.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:34 ET. No prices; not investment advice.